Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02688556
Other study ID # OTX-101-2016-001
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date February 2016
Est. completion date December 2016

Study information

Verified date November 2021
Source Sun Pharmaceutical Industries Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double-masked, vehicle-controlled study of the safety and efficacy of OTX-101 (0.09% cyclosporine nanomicellar solution) in the treatment of keratoconjunctivitis sicca to be conducted at approximately 50 sites.


Recruitment information / eligibility

Status Completed
Enrollment 745
Est. completion date December 2016
Est. primary completion date November 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - History of dry eye syndrome (KCS) for a period of at least 6 months - Clinical diagnosis of bilateral KCS - Lissamine green conjunctival staining sum score of = 3 to = 9 out of a total possible score of 12 (scoring excludes superior zones 2 and 4) in the same eye at both the Screening and Baseline Visits. - Global symptom score (SANDE) = 40 mm at both the Screening and Baseline Visits - Corrected Snellen visual acuity (VA) of better than 20/200 in each eye. Exclusion Criteria: - Use of cyclosporine ophthalmic emulsion 0.05% (Restasis®) within 3 months prior to the Screening Visit. - Previous treatment failure (lack of efficacy) with cyclosporine ophthalmic emulsion 0.05% (Restasis). - Diagnosis of Sjögren's disease ? 5 years prior to the Screening Visit. - Clinical diagnosis or any history of seasonal and/or perennial allergic conjunctivitis. - Use of systemic or topical medications within 7 days prior to the Screening Visit or during the study period that are known to cause dry eye. - Use of any topical ophthalmic medications, prescription (including anti-glaucoma medications) or over the counter (including artificial tears), other than the assigned study medication during the study period. - Current active eye disease other than dry wyw syndrome (i.e., any disease for which topical or systemic ophthalmic medication is necessary). - History of herpes keratitis. - Corneal transplant - Corneal refractive surgery within 6 months prior to the Screening Visit or postoperative refractive surgery symptoms of dryness that have not resolved. - Cataract surgery within 3 months prior to the Screening Visit.

Study Design


Intervention

Drug:
cyclosporine

vehicle of OTX-101


Locations

Country Name City State
United States Cincinnati Eye Institute Edgewood Kentucky
United States Fifth Avenue Eye Associates New York New York
United States Martel Eye Medical Group Rancho Cordova California

Sponsors (1)

Lead Sponsor Collaborator
Sun Pharmaceutical Industries Limited

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tear Production Percentage of Eyes with Increase from Baseline of = 10 mm in Schirmer's Test Score Baseline and 12 weeks
Secondary Conjunctival Staining change from baseline in total conjunctival staining score (lissamine green, modified National Eye Institute scale) at 12 weeks.
Conjunctival Lissamine Green Staining Grades ranged from 0 (No punctate stain in zone) to 3 (Densely concentrated micropunctate stain spots)
Baseline and 12 weeks
Secondary Central Corneal Staining change from baseline in central corneal staining score (fluorescein, modified NEI/FDA scale) at 12 weeks.
The Expanded National Eye Institute (NEI)/Industry Workshop Scale for Corneal Staining Score was used to grade each of the 5 areas of the cornea on a 0 (No punctate stain in area) to 4 (Severe diffuse (coalescent) macropunctate stain of the area) scale.
Baseline and 12 weeks
Secondary Symptom Score change from baseline in modified Symptom Assessment in Dry Eye (SANDE) score at 12 weeks.
A modified SANDE instrument was used to evaluate dry eye symptoms at each visit.
Subjects were asked to indicate:
frequency of dry and irritated eyes on a scale of 0 (rarely) to 100 (all the time); and
severity of dry eyes on a scale of 0 (very mild) to 100 (severe) The global symptom score is the square root of the frequency score times the severity score and will be completed at each visit. (range 0 to 100)
Negative change from baseline indicates improvement.
Baseline and 12 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05618730 - Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B Phase 1
Completed NCT02254265 - Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca Phase 2/Phase 3
Completed NCT00883649 - Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye N/A
Completed NCT00128245 - Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca Phase 2
Completed NCT00717418 - Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease N/A
Enrolling by invitation NCT03436576 - Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye Phase 3
Completed NCT04147650 - Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome Phase 2/Phase 3
Completed NCT01733992 - A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease Phase 1
Completed NCT00987727 - Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Phase 4
Completed NCT00788229 - Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome Phase 2
Completed NCT00554879 - Acupuncture Treatment of Dry Eye N/A
Completed NCT00407043 - Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Phase 4
Completed NCT00001731 - Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops Phase 2
Recruiting NCT03953703 - Levocarnitine for Dry Eye in Sjogren's Syndrome Phase 2
Withdrawn NCT03398018 - Repository Corticotropin Injection in Keratoconjunctivitis Sicca Phase 4
Recruiting NCT02066896 - Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome Phase 3
Completed NCT02139033 - A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome Phase 4
Terminated NCT01213342 - Omega-3 Fatty Acid Supplements and Dry Eye N/A
Completed NCT00201955 - Study of Rebamipide Eye Drops to Treat Dry Eye Phase 3
Completed NCT00201981 - Study of Rebamipide Eye Drops to Treat Dry Eye Phase 3